Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Good news for young sarcoma patients: a new study shows that children and young adults with nonmetastatic soft tissue sarcoma who undergo margin-negative (R0) resection have a remarkably low local recurrence rate of just 4.4% at five years. The findings suggest that even close — but cancer-free — surgical margins may be sufficient, potentially allowing surgeons to spare more limb function in young patients.
A new study published in JAMA Surgery brings encouraging news for young patients battling soft tissue sarcoma. Researchers from Stanford University found that children and young adults with nonmetastatic nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) who underwent margin-negative (R0) resection as part of a risk-adapted treatment plan had a five-year local recurrence rate of just 4.4% — a notably low figure that could reshape surgical decision-making.
The study analyzed 266 patients and found that recurrence rates varied by treatment approach: 5.6% for surgery alone and 2.3% for surgery combined with chemotherapy. Wider surgical margins were associated with lower recurrence, but even narrower cancer-free margins showed strong outcomes.
By the Numbers:
Why it matters: These findings give surgeons a clearer roadmap for balancing cancer control with quality of life. By confirming that close but cancer-free margins can be sufficient, surgeons may be able to preserve more limb function in young patients — a critical consideration for long-term wellbeing.
